Trump signs order to speed review of psychedelics, including the controversial drug ibogaine

President Donald Trump signed an executive order to accelerate the review of psychedelic drugs, including ibogaine, which is controversial due to safety risks but advocated for by veterans and conservative lawmakers. The FDA will fast-track approvals using national priority vouchers, marking the first time psychedelics receive such expedited review. The move aims to expand access to potential treatments for conditions like PTSD and opioid addiction.